Search - tctmd.com

Displaying 701 - 720 of 2221

Sort: Relevancy | Date

News Daily News

Post-TAVR Myocardial Injury Linked to Mortality

Caitlin E. Cox

November 02, 2015

News Industry News

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

November 02, 2015

Presentation

LVAD Therapy in End-Stage Heart Disease

Presenter: Matthias Loebe

October 30, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Daily News

More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions

L.A. McKeown

October 26, 2015

News Industry News

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

October 26, 2015

News Daily News

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

Todd Neale

October 26, 2015

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

News Industry News

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

October 21, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

New Noninvasive Methods for Assessing Valvular Heart Disease

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Presentation TCT 2015

Assessing Postdevice Paravalvular Aortic Regurgitation

Presenter: Jeroen J. Bax, Paul A. Grayburn, Rebecca T. Hahn

October 15, 2015

Presentation TCT 2015

What Defines Severe MR Post-AHA/ACC Guidelines?

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Advertisement

Post-TAVR Myocardial Injury Linked to Mortality

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

LVAD Therapy in End-Stage Heart Disease

Younger Women With STEMI More Likely Than Men to Die In-Hospital

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

My Takeaways From TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

New Noninvasive Methods for Assessing Valvular Heart Disease

Assessing Postdevice Paravalvular Aortic Regurgitation

What Defines Severe MR Post-AHA/ACC Guidelines?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content